BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 25, 2008
 |  BioCentury  |  Analyst Picks & Changes

Analysts picks & changes

Analysts picks & changes

Company Bank Analyst Coverage Opinion Wk chg 8/22 cls
Alnylam (NASDAQ:ALNY) Leerink Jonas Alsenas New Underperform -14% $29.88
Alsenas assigned a target of $14-$16 per share. He thinks the company’s RNA interference (RNAi) technology is more suited for research purposes than therapeutics, which he said have historically failed due to poor pharmacokinetics and tissue delivery profiles. He also noted that ALN-RSV01, a respiratory syncytial virus specific short interfering RNA (siRNA) to treat RSV infection, has had “difficult to interpret and underwhelming” Phase II data. He expects it to have difficulty competing with Synagis palivizumab from the MedImmune subsidiary of AstraZeneca (LSE:AZN; NYSE:AZN). He expects the company to use its $538M in cash at June 30 to “diversify” or “forward integrate” by acquiring another...

Read the full 774 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >